#Bcl2
YouTube Grand Piano - Play it on YouTube with your number keys

www.youtube.com/watch?v=BcL2...
YouTube Grand Piano - Play it on YouTube with your number keys
YouTube video by Chill Buddies
www.youtube.com
November 9, 2026 at 4:10 AM
RRIDs were included in this in Journal of Experimental Medicine paper. We value the author's support of reproducibility. #RRID #OpenResearch #ReproducibleResearch
SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma
Read the full paper: SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma
doi.org
October 30, 2026 at 7:04 AM
“miR-195-5p controls apoptotic cascade by regulating the XIAP/BCL2/Survivin network in colorectal cancer”

A promising pleiotropic #TumorSuppressor capable of restoring apoptotic sensitivity in #CRC ⤵️
www.nature.com/articles/s41...
miR-195-5p controls apoptotic cascade by regulating the XIAP/BCL2/Survivin network in colorectal cancer - Cell Death Discovery
Cell Death Discovery - miR-195-5p controls apoptotic cascade by regulating the XIAP/BCL2/Survivin network in colorectal cancer
www.nature.com
October 28, 2026 at 9:32 AM
" créer c'est résister, résister c'est créer " www.youtube.com/watch?v=BCl2...
October 25, 2026 at 9:42 PM
InnoCare's mesutoclax-orelabrutinib combination has cleared China's NMPA for a registrational Phase III trial in relapsed or refractory marginal zone lymphoma. A dual BCL2/BTK approach in a hard-to-treat setting.
InnoCare wins CDE nod for Phase III mesutoclax combo in r/r MZL
China's NMPA has approved a registrational Phase III study of InnoCare's BCL2 inhibitor mesutoclax plus orelabrutinib in relapsed or refractory marginal zone lymphoma.
thebiotechtimes.com
October 20, 2026 at 5:00 AM
RRIDs were included in this in Nucleic Acids Research paper. RRIDs improve reproducibility in scientific research. #STMpublishing #BetterScience #OpenScience
DNA secondary structures in BCL2 and MYC elicit activation-induced cytidine deaminase binding and activity
Read the full paper: DNA secondary structures in BCL2 and MYC elicit activation-induced cytidine deaminase binding and activity
doi.org
October 9, 2026 at 7:06 AM
RRIDs were included in this paper. RRIDs improve reproducibility in scientific research. #RRID #ReproducibleResearch #methodsmatter
PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade
Read the full paper: PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade
doi.org
October 7, 2026 at 7:01 AM
Can anti-BCL2 therapy achieve durable clearance of giant congenital melanocytic nevus?

BCL2 inhibition targets senescent and proliferative cells while inducing neutrophil extracellular traps and T-cell responses.

STTT #OpenAccess: doi.org/10.1038/s413...
#Apoptosis #CancerTherapy
October 6, 2026 at 3:45 PM
#Bcl2 family proteins regulate cell survival and death, with roles spanning autophagy, calcium #homeostasis, and mitochondrial dynamics, offering therapeutic promise through BH3 mimetics. #medsky

To read: doi.org/10.1007/s115...

#currentmedicalscience #CellBiology
October 2, 2026 at 2:30 PM
>m~0-M=LysJ5{Roeo.f{_.(bcL2<WG;(
September 30, 2026 at 3:20 PM
Integrating single-cell imaging, multi-omics analyses, mechanistic studies, therapeutic modeling & a Phase Ib trial, our study identifies BCL-2 as a therapeutic vulnerability across heterogeneous CRPC.

Congrats to Anmbreen Jamroze, Dean G. Tang, Gurkamal Chatta & our team!
#ProstateCancer #BCL2
September 30, 2026 at 3:35 PM
Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed. https://www.medpagetoday.com/hematologyoncology/lymphoma/122957
Study Warns on Venetoclax in Double-Hit Lymphoma
Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen
www.medpagetoday.com
September 15, 2026 at 2:11 AM
📈 Responses were shown in patients with R/R CLL who had received both a covalent BTK inhibitor and a BCL2 inhibitor, according to a pooled analysis of BRUIN trials.

Read more here ➡️: www.onclive.com/view/pirtobr...

#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social
Pirtobrutinib Elicits Responses After Covalent BTK Inhibitor Failure in R/R CLL | OncLive
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
www.onclive.com
September 14, 2026 at 8:45 PM
This somehow unlocked the memory of Mike asking Okung on a really early episode of the Real Rob Report what BDR stood for in his Twitter handle BDR76. Anyway I believe in BCL2.
September 14, 2026 at 1:49 AM
Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma https://www.biorxiv.org/content/10.64898/2026.09.06.749004v1
September 10, 2026 at 7:52 PM
Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma https://www.biorxiv.org/content/10.64898/2026.09.06.749004v1
September 10, 2026 at 7:52 PM
With sonrotoclax now the first BCL2 inhibitor approved in MCL, @LymphClinician of @cityofhope breaks down where the agent fits in the relapsed/refractory treatment paradigm #lymsm #oncology www.onclive.com/view/sonroto...
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL | OncLive
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
www.onclive.com
September 4, 2026 at 1:11 PM
Don't miss Silke Johannsen, Roland K. O. Sigel et al's recent article

#ChemSciCovers

'Elucidating the solution structure of the monomolecular BCL2 RNA G-quadruplex: a new robust NMR assignment approach'

🔗 doi.org/10.1039/D5SC...
June 8, 2025 at 9:00 AM
Just stumbled on this 💎 of a paper at my end-of-the-year review of the #apoptosis #Bax #Bcl2 literature (i.e., trying to get that last paper out). Can't stress enough how glad I am that this gets reported and has a venue in a high profile journal! 🔬🧪👍👍👍 @natureportfolio.bsky.social
Why Bax detection in >1400 publications might be flawed - Cell Death & Disease
Cell Death & Disease - Why Bax detection in &gt;1400 publications might be flawed
www.nature.com
December 23, 2024 at 2:22 PM
Hello Sienna! Great paper do you happen to know if BCL proteins are up during general activation of microglia? I am wondering if microglia survive a DAMP signal also up-regulates BCL2.
January 28, 2025 at 6:40 AM
Image of the Week!

Contributed by: Shikha Malhotra, M.B.B.S., M.D.
Textbook topic: Stains & CD markers
Diagnosis: Follicular lymphoma, BCL2 IHC
Textbook topic link: www.pathologyoutlines.com/topic/stains...

#Pathology #PathologyOutlines #PathSky
July 1, 2026 at 5:46 PM